aluates Reports

$ 0.0

Automative

Global Immune Thrombocytopenic Purpura Therapeutics Market Research Report 2024

Published Date: August 2024

Report Code: QYRE-Auto-4I14018

Global Immune Thrombocytopenic Purpura Therapeutics Market Research Report 2023

BUY CHAPTERS

Global Immune Thrombocytopenic Purpura Therapeutics Market Research Report 2024

Code: QYRE-Auto-4I14018

Report

August 2024

Pages:89

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Amgen Inc

Baxalta Incorporated

Boehringer Ingelheim GmbH

Bristol Myers Squibb Company

Eisai Co Ltd

Hansa Medical AB

Immunomedics

Intas Pharmaceuticals Ltd

Jiangsu Hengrui Medicine Co Ltd

Merck& Co. Inc

Momenta Pharmaceuticals Inc

Novartis

Pfizer Inc

Immune Thrombocytopenic Purpura Therapeutics Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Immune Thrombocytopenic Purpura Therapeutics Market

The global Immune Thrombocytopenic Purpura Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Immune Thrombocytopenic Purpura Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Immune Thrombocytopenic Purpura Therapeutics.

Report Scope

The Immune Thrombocytopenic Purpura Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Immune Thrombocytopenic Purpura Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Immune Thrombocytopenic Purpura Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Immune Thrombocytopenic Purpura Therapeutics Market Report

Report Metric	Details
Report Name	Immune Thrombocytopenic Purpura Therapeutics Market
CAGR	5%
Segment by Type	Eltrombopag Olamine Fostamatinib Disodium GL-2045 Avatrombopag BI-655064 Others
Segment by Application	Hospital Clinic Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Amgen Inc., Baxalta Incorporated, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eisai, Hansa Medical AB, Immunomedics, Inc., Intas Pharmaceuticals Ltd., Jiangsu Hengrui Medicine Co., Ltd., Merck & Co., Inc., Momenta Pharmaceuticals, Inc., Novartis AG, Pfizer Inc.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Immune Thrombocytopenic Purpura Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Immune Thrombocytopenic Purpura Therapeutics Market report?

Ans: The main players in the Immune Thrombocytopenic Purpura Therapeutics Market are Amgen Inc., Baxalta Incorporated, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eisai, Hansa Medical AB, Immunomedics, Inc., Intas Pharmaceuticals Ltd., Jiangsu Hengrui Medicine Co., Ltd., Merck & Co., Inc., Momenta Pharmaceuticals, Inc., Novartis AG, Pfizer Inc.

What are the Application segmentation covered in the Immune Thrombocytopenic Purpura Therapeutics Market report?

Ans: The Applications covered in the Immune Thrombocytopenic Purpura Therapeutics Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Immune Thrombocytopenic Purpura Therapeutics Market report?

Ans: The Types covered in the Immune Thrombocytopenic Purpura Therapeutics Market report are Eltrombopag Olamine, Fostamatinib Disodium, GL-2045, Avatrombopag, BI-655064, Others

Recommended Reports

Autoimmune Disease Therapy

Blood & Plasma Disorders

Immunology & Vaccines

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Immune Thrombocytopenic Purpura Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Eltrombopag Olamine

1.2.3 Fostamatinib Disodium

1.2.4 GL-2045

1.2.5 Avatrombopag

1.2.6 BI-655064

1.2.7 Others

1.3 Market by Application

1.3.1 Global Immune Thrombocytopenic Purpura Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Others

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Immune Thrombocytopenic Purpura Therapeutics Market Perspective (2019-2030)

2.2 Immune Thrombocytopenic Purpura Therapeutics Growth Trends by Region

2.2.1 Global Immune Thrombocytopenic Purpura Therapeutics Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Immune Thrombocytopenic Purpura Therapeutics Historic Market Size by Region (2019-2024)

2.2.3 Immune Thrombocytopenic Purpura Therapeutics Forecasted Market Size by Region (2025-2030)

2.3 Immune Thrombocytopenic Purpura Therapeutics Market Dynamics

2.3.1 Immune Thrombocytopenic Purpura Therapeutics Industry Trends

2.3.2 Immune Thrombocytopenic Purpura Therapeutics Market Drivers

2.3.3 Immune Thrombocytopenic Purpura Therapeutics Market Challenges

2.3.4 Immune Thrombocytopenic Purpura Therapeutics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Immune Thrombocytopenic Purpura Therapeutics Players by Revenue

3.1.1 Global Top Immune Thrombocytopenic Purpura Therapeutics Players by Revenue (2019-2024)

3.1.2 Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Players (2019-2024)

3.2 Global Immune Thrombocytopenic Purpura Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Immune Thrombocytopenic Purpura Therapeutics Revenue

3.4 Global Immune Thrombocytopenic Purpura Therapeutics Market Concentration Ratio

3.4.1 Global Immune Thrombocytopenic Purpura Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Immune Thrombocytopenic Purpura Therapeutics Revenue in 2023

3.5 Immune Thrombocytopenic Purpura Therapeutics Key Players Head office and Area Served

3.6 Key Players Immune Thrombocytopenic Purpura Therapeutics Product Solution and Service

3.7 Date of Enter into Immune Thrombocytopenic Purpura Therapeutics Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Immune Thrombocytopenic Purpura Therapeutics Breakdown Data by Type

4.1 Global Immune Thrombocytopenic Purpura Therapeutics Historic Market Size by Type (2019-2024)

4.2 Global Immune Thrombocytopenic Purpura Therapeutics Forecasted Market Size by Type (2025-2030)

5 Immune Thrombocytopenic Purpura Therapeutics Breakdown Data by Application

5.1 Global Immune Thrombocytopenic Purpura Therapeutics Historic Market Size by Application (2019-2024)

5.2 Global Immune Thrombocytopenic Purpura Therapeutics Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Immune Thrombocytopenic Purpura Therapeutics Market Size (2019-2030)

6.2 North America Immune Thrombocytopenic Purpura Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2019-2024)

6.4 North America Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Immune Thrombocytopenic Purpura Therapeutics Market Size (2019-2030)

7.2 Europe Immune Thrombocytopenic Purpura Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2019-2024)

7.4 Europe Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size (2019-2030)

8.2 Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size by Region (2019-2024)

8.4 Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size (2019-2030)

9.2 Latin America Immune Thrombocytopenic Purpura Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2019-2024)

9.4 Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size (2019-2030)

10.2 Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2019-2024)

10.4 Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Amgen Inc.

11.1.1 Amgen Inc. Company Detail

11.1.2 Amgen Inc. Business Overview

11.1.3 Amgen Inc. Immune Thrombocytopenic Purpura Therapeutics Introduction

11.1.4 Amgen Inc. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024)

11.1.5 Amgen Inc. Recent Development

11.2 Baxalta Incorporated

11.2.1 Baxalta Incorporated Company Detail

11.2.2 Baxalta Incorporated Business Overview

11.2.3 Baxalta Incorporated Immune Thrombocytopenic Purpura Therapeutics Introduction

11.2.4 Baxalta Incorporated Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024)

11.2.5 Baxalta Incorporated Recent Development

11.3 Boehringer Ingelheim GmbH

11.3.1 Boehringer Ingelheim GmbH Company Detail

11.3.2 Boehringer Ingelheim GmbH Business Overview

11.3.3 Boehringer Ingelheim GmbH Immune Thrombocytopenic Purpura Therapeutics Introduction

11.3.4 Boehringer Ingelheim GmbH Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024)

11.3.5 Boehringer Ingelheim GmbH Recent Development

11.4 Bristol-Myers Squibb Company

11.4.1 Bristol-Myers Squibb Company Company Detail

11.4.2 Bristol-Myers Squibb Company Business Overview

11.4.3 Bristol-Myers Squibb Company Immune Thrombocytopenic Purpura Therapeutics Introduction

11.4.4 Bristol-Myers Squibb Company Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024)

11.4.5 Bristol-Myers Squibb Company Recent Development

11.5 Eisai

11.5.1 Eisai Company Detail

11.5.2 Eisai Business Overview

11.5.3 Eisai Immune Thrombocytopenic Purpura Therapeutics Introduction

11.5.4 Eisai Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024)

11.5.5 Eisai Recent Development

11.6 Hansa Medical AB

11.6.1 Hansa Medical AB Company Detail

11.6.2 Hansa Medical AB Business Overview

11.6.3 Hansa Medical AB Immune Thrombocytopenic Purpura Therapeutics Introduction

11.6.4 Hansa Medical AB Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024)

11.6.5 Hansa Medical AB Recent Development

11.7 Immunomedics, Inc.

11.7.1 Immunomedics, Inc. Company Detail

11.7.2 Immunomedics, Inc. Business Overview

11.7.3 Immunomedics, Inc. Immune Thrombocytopenic Purpura Therapeutics Introduction

11.7.4 Immunomedics, Inc. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024)

11.7.5 Immunomedics, Inc. Recent Development

11.8 Intas Pharmaceuticals Ltd.

11.8.1 Intas Pharmaceuticals Ltd. Company Detail

11.8.2 Intas Pharmaceuticals Ltd. Business Overview

11.8.3 Intas Pharmaceuticals Ltd. Immune Thrombocytopenic Purpura Therapeutics Introduction

11.8.4 Intas Pharmaceuticals Ltd. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024)

11.8.5 Intas Pharmaceuticals Ltd. Recent Development

11.9 Jiangsu Hengrui Medicine Co., Ltd.

11.9.1 Jiangsu Hengrui Medicine Co., Ltd. Company Detail

11.9.2 Jiangsu Hengrui Medicine Co., Ltd. Business Overview

11.9.3 Jiangsu Hengrui Medicine Co., Ltd. Immune Thrombocytopenic Purpura Therapeutics Introduction

11.9.4 Jiangsu Hengrui Medicine Co., Ltd. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024)

11.9.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Development

11.10 Merck & Co., Inc.

11.10.1 Merck & Co., Inc. Company Detail

11.10.2 Merck & Co., Inc. Business Overview

11.10.3 Merck & Co., Inc. Immune Thrombocytopenic Purpura Therapeutics Introduction

11.10.4 Merck & Co., Inc. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024)

11.10.5 Merck & Co., Inc. Recent Development

11.11 Momenta Pharmaceuticals, Inc.

11.11.1 Momenta Pharmaceuticals, Inc. Company Detail

11.11.2 Momenta Pharmaceuticals, Inc. Business Overview

11.11.3 Momenta Pharmaceuticals, Inc. Immune Thrombocytopenic Purpura Therapeutics Introduction

11.11.4 Momenta Pharmaceuticals, Inc. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024)

11.11.5 Momenta Pharmaceuticals, Inc. Recent Development

11.12 Novartis AG

11.12.1 Novartis AG Company Detail

11.12.2 Novartis AG Business Overview

11.12.3 Novartis AG Immune Thrombocytopenic Purpura Therapeutics Introduction

11.12.4 Novartis AG Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024)

11.12.5 Novartis AG Recent Development

11.13 Pfizer Inc.

11.13.1 Pfizer Inc. Company Detail

11.13.2 Pfizer Inc. Business Overview

11.13.3 Pfizer Inc. Immune Thrombocytopenic Purpura Therapeutics Introduction

11.13.4 Pfizer Inc. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024)

11.13.5 Pfizer Inc. Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Amgen Inc

Baxalta Incorporated

Boehringer Ingelheim GmbH

Bristol Myers Squibb Company

Eisai Co Ltd

Hansa Medical AB

Immunomedics

Intas Pharmaceuticals Ltd

Jiangsu Hengrui Medicine Co Ltd

Merck& Co. Inc

Momenta Pharmaceuticals Inc

Novartis

Pfizer Inc

List of Tables

Table 1. Global Immune Thrombocytopenic Purpura Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Eltrombopag Olamine

Table 3. Key Players of Fostamatinib Disodium

Table 4. Key Players of GL-2045

Table 5. Key Players of Avatrombopag

Table 6. Key Players of BI-655064

Table 7. Key Players of Others

Table 8. Global Immune Thrombocytopenic Purpura Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 9. Global Immune Thrombocytopenic Purpura Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 10. Global Immune Thrombocytopenic Purpura Therapeutics Market Size by Region (2019-2024) & (US$ Million)

Table 11. Global Immune Thrombocytopenic Purpura Therapeutics Market Share by Region (2019-2024)

Table 12. Global Immune Thrombocytopenic Purpura Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 13. Global Immune Thrombocytopenic Purpura Therapeutics Market Share by Region (2025-2030)

Table 14. Immune Thrombocytopenic Purpura Therapeutics Market Trends

Table 15. Immune Thrombocytopenic Purpura Therapeutics Market Drivers

Table 16. Immune Thrombocytopenic Purpura Therapeutics Market Challenges

Table 17. Immune Thrombocytopenic Purpura Therapeutics Market Restraints

Table 18. Global Immune Thrombocytopenic Purpura Therapeutics Revenue by Players (2019-2024) & (US$ Million)

Table 19. Global Immune Thrombocytopenic Purpura Therapeutics Market Share by Players (2019-2024)

Table 20. Global Top Immune Thrombocytopenic Purpura Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immune Thrombocytopenic Purpura Therapeutics as of 2023)

Table 21. Ranking of Global Top Immune Thrombocytopenic Purpura Therapeutics Companies by Revenue (US$ Million) in 2023

Table 22. Global 5 Largest Players Market Share by Immune Thrombocytopenic Purpura Therapeutics Revenue (CR5 and HHI) & (2019-2024)

Table 23. Key Players Headquarters and Area Served

Table 24. Key Players Immune Thrombocytopenic Purpura Therapeutics Product Solution and Service

Table 25. Date of Enter into Immune Thrombocytopenic Purpura Therapeutics Market

Table 26. Mergers & Acquisitions, Expansion Plans

Table 27. Global Immune Thrombocytopenic Purpura Therapeutics Market Size by Type (2019-2024) & (US$ Million)

Table 28. Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Type (2019-2024)

Table 29. Global Immune Thrombocytopenic Purpura Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 30. Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Type (2025-2030)

Table 31. Global Immune Thrombocytopenic Purpura Therapeutics Market Size by Application (2019-2024) & (US$ Million)

Table 32. Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Application (2019-2024)

Table 33. Global Immune Thrombocytopenic Purpura Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 34. Global Immune Thrombocytopenic Purpura Therapeutics Revenue Market Share by Application (2025-2030)

Table 35. North America Immune Thrombocytopenic Purpura Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 36. North America Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 37. North America Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 38. Europe Immune Thrombocytopenic Purpura Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 39. Europe Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 40. Europe Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 41. Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 42. Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size by Region (2019-2024) & (US$ Million)

Table 43. Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size by Region (2025-2030) & (US$ Million)

Table 44. Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 45. Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 46. Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 47. Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 48. Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 50. Amgen Inc. Company Detail

Table 51. Amgen Inc. Business Overview

Table 52. Amgen Inc. Immune Thrombocytopenic Purpura Therapeutics Product

Table 53. Amgen Inc. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024) & (US$ Million)

Table 54. Amgen Inc. Recent Development

Table 55. Baxalta Incorporated Company Detail

Table 56. Baxalta Incorporated Business Overview

Table 57. Baxalta Incorporated Immune Thrombocytopenic Purpura Therapeutics Product

Table 58. Baxalta Incorporated Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024) & (US$ Million)

Table 59. Baxalta Incorporated Recent Development

Table 60. Boehringer Ingelheim GmbH Company Detail

Table 61. Boehringer Ingelheim GmbH Business Overview

Table 62. Boehringer Ingelheim GmbH Immune Thrombocytopenic Purpura Therapeutics Product

Table 63. Boehringer Ingelheim GmbH Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024) & (US$ Million)

Table 64. Boehringer Ingelheim GmbH Recent Development

Table 65. Bristol-Myers Squibb Company Company Detail

Table 66. Bristol-Myers Squibb Company Business Overview

Table 67. Bristol-Myers Squibb Company Immune Thrombocytopenic Purpura Therapeutics Product

Table 68. Bristol-Myers Squibb Company Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024) & (US$ Million)

Table 69. Bristol-Myers Squibb Company Recent Development

Table 70. Eisai Company Detail

Table 71. Eisai Business Overview

Table 72. Eisai Immune Thrombocytopenic Purpura Therapeutics Product

Table 73. Eisai Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024) & (US$ Million)

Table 74. Eisai Recent Development

Table 75. Hansa Medical AB Company Detail

Table 76. Hansa Medical AB Business Overview

Table 77. Hansa Medical AB Immune Thrombocytopenic Purpura Therapeutics Product

Table 78. Hansa Medical AB Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024) & (US$ Million)

Table 79. Hansa Medical AB Recent Development

Table 80. Immunomedics, Inc. Company Detail

Table 81. Immunomedics, Inc. Business Overview

Table 82. Immunomedics, Inc. Immune Thrombocytopenic Purpura Therapeutics Product

Table 83. Immunomedics, Inc. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024) & (US$ Million)

Table 84. Immunomedics, Inc. Recent Development

Table 85. Intas Pharmaceuticals Ltd. Company Detail

Table 86. Intas Pharmaceuticals Ltd. Business Overview

Table 87. Intas Pharmaceuticals Ltd. Immune Thrombocytopenic Purpura Therapeutics Product

Table 88. Intas Pharmaceuticals Ltd. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024) & (US$ Million)

Table 89. Intas Pharmaceuticals Ltd. Recent Development

Table 90. Jiangsu Hengrui Medicine Co., Ltd. Company Detail

Table 91. Jiangsu Hengrui Medicine Co., Ltd. Business Overview

Table 92. Jiangsu Hengrui Medicine Co., Ltd. Immune Thrombocytopenic Purpura Therapeutics Product

Table 93. Jiangsu Hengrui Medicine Co., Ltd. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024) & (US$ Million)

Table 94. Jiangsu Hengrui Medicine Co., Ltd. Recent Development

Table 95. Merck & Co., Inc. Company Detail

Table 96. Merck & Co., Inc. Business Overview

Table 97. Merck & Co., Inc. Immune Thrombocytopenic Purpura Therapeutics Product

Table 98. Merck & Co., Inc. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024) & (US$ Million)

Table 99. Merck & Co., Inc. Recent Development

Table 100. Momenta Pharmaceuticals, Inc. Company Detail

Table 101. Momenta Pharmaceuticals, Inc. Business Overview

Table 102. Momenta Pharmaceuticals, Inc. Immune Thrombocytopenic Purpura Therapeutics Product

Table 103. Momenta Pharmaceuticals, Inc. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024) & (US$ Million)

Table 104. Momenta Pharmaceuticals, Inc. Recent Development

Table 105. Novartis AG Company Detail

Table 106. Novartis AG Business Overview

Table 107. Novartis AG Immune Thrombocytopenic Purpura Therapeutics Product

Table 108. Novartis AG Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024) & (US$ Million)

Table 109. Novartis AG Recent Development

Table 110. Pfizer Inc. Company Detail

Table 111. Pfizer Inc. Business Overview

Table 112. Pfizer Inc. Immune Thrombocytopenic Purpura Therapeutics Product

Table 113. Pfizer Inc. Revenue in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024) & (US$ Million)

Table 114. Pfizer Inc. Recent Development

Table 115. Research Programs/Design for This Report

Table 116. Key Data Information from Secondary Sources

Table 117. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Immune Thrombocytopenic Purpura Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Immune Thrombocytopenic Purpura Therapeutics Market Share by Type: 2023 VS 2030

Figure 3. Eltrombopag Olamine Features

Figure 4. Fostamatinib Disodium Features

Figure 5. GL-2045 Features

Figure 6. Avatrombopag Features

Figure 7. BI-655064 Features

Figure 8. Others Features

Figure 9. Global Immune Thrombocytopenic Purpura Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 10. Global Immune Thrombocytopenic Purpura Therapeutics Market Share by Application: 2023 VS 2030

Figure 11. Hospital Case Studies

Figure 12. Clinic Case Studies

Figure 13. Others Case Studies

Figure 14. Immune Thrombocytopenic Purpura Therapeutics Report Years Considered

Figure 15. Global Immune Thrombocytopenic Purpura Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 16. Global Immune Thrombocytopenic Purpura Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 17. Global Immune Thrombocytopenic Purpura Therapeutics Market Share by Region: 2023 VS 2030

Figure 18. Global Immune Thrombocytopenic Purpura Therapeutics Market Share by Players in 2023

Figure 19. Global Top Immune Thrombocytopenic Purpura Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immune Thrombocytopenic Purpura Therapeutics as of 2023)

Figure 20. The Top 10 and 5 Players Market Share by Immune Thrombocytopenic Purpura Therapeutics Revenue in 2023

Figure 21. North America Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. North America Immune Thrombocytopenic Purpura Therapeutics Market Share by Country (2019-2030)

Figure 23. United States Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Canada Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Europe Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Europe Immune Thrombocytopenic Purpura Therapeutics Market Share by Country (2019-2030)

Figure 27. Germany Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. France Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. U.K. Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Italy Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Russia Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Nordic Countries Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Asia-Pacific Immune Thrombocytopenic Purpura Therapeutics Market Share by Region (2019-2030)

Figure 35. China Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Japan Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. South Korea Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Southeast Asia Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. India Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Australia Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Latin America Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Latin America Immune Thrombocytopenic Purpura Therapeutics Market Share by Country (2019-2030)

Figure 43. Mexico Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Brazil Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Middle East & Africa Immune Thrombocytopenic Purpura Therapeutics Market Share by Country (2019-2030)

Figure 47. Turkey Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Saudi Arabia Immune Thrombocytopenic Purpura Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 49. Amgen Inc. Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024)

Figure 50. Baxalta Incorporated Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024)

Figure 51. Boehringer Ingelheim GmbH Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024)

Figure 52. Bristol-Myers Squibb Company Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024)

Figure 53. Eisai Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024)

Figure 54. Hansa Medical AB Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024)

Figure 55. Immunomedics, Inc. Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024)

Figure 56. Intas Pharmaceuticals Ltd. Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024)

Figure 57. Jiangsu Hengrui Medicine Co., Ltd. Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024)

Figure 58. Merck & Co., Inc. Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024)

Figure 59. Momenta Pharmaceuticals, Inc. Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024)

Figure 60. Novartis AG Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024)

Figure 61. Pfizer Inc. Revenue Growth Rate in Immune Thrombocytopenic Purpura Therapeutics Business (2019-2024)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Therapeutic Apheresis Devices Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Heparin Induced Thrombocytopenia HIT Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global IPV Vaccine Market Research Report 2025

Autoimmune Therapeutics Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Autoimmune Diseases Treatment Market Research Report 2024

Plasma Derived Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Immune System Allergy Treatment Market Research Report 2025

Drug Induced Immune Hemolytic Anemia Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Lung Disease Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Thrombolytic Treatment Market Research Report 2024

Global Essential Thrombocythemia Drug Market Research Report 2025

Global Mercaptopurine API Market Research Report 2025

Cell Therapy Technologies Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Next Generation Immunology Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Graft Versus Host Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Lung Disease Therapeutic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Anti infectious Disease Drugs Market Research Report 2025

Global Complement Drug for Blood Disease Market Research Report 2024

Rheumatology Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions